stockportfolio.pro
Stocks / AKTS vs EYPT
AKTS vs EYPT
Aktis Oncology, Inc. and EyePoint, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Aktis Oncology, Inc. (AKTS) | EyePoint, Inc. (EYPT) | |
|---|---|---|
| Market cap | $1.0B | $1.0B |
| Revenue (latest FY) | $6.50M | $31.37M |
| Net income (latest FY) | $-63.73M | $-231.96M |
| Revenue growth (5y CAGR) | — | -1.8% |
| Net margin | -980.9% | -739.4% |
| Return on equity | 43.6% | -75.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AKTS — free Open EYPT — freeFrequently asked questions
Which is bigger, AKTS or EYPT?
EyePoint, Inc. is larger by market capitalization — $1.0B versus $1.0B.
Which grows faster, AKTS or EYPT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.